The ATP7B Target: Why Wilson’s Disease Demands New Approaches

Wilson’s disease (WD) is a rare autosomal recessive disorder caused by mutations in the ATP7B gene, resulting in deficient production of copper-transporting ATPase2 and pathological copper accumulation in the liver, brain, and other tissues — a condition that is universally fatal without treatment. The disease mechanism is well-defined: ATP7B protein loss impairs both biliary copper excretion and the incorporation of copper into ceruloplasmin, the serum ferroxidase that carries more than 95% of plasma copper in healthy individuals. Without functional ATP7B, copper spills from the liver into the brain, triggering progressive neurological and hepatic injury.

More than 500 associated ATP7B mutations have been identified, and most Wilson’s disease patients are compound heterozygotes — carrying two different mutations — which complicates genotype-phenotype correlations and makes population-wide treatment standardisation difficult. Most patients are diagnosed before age 30, underscoring the importance of early pharmacological intervention. A case report from Tianjin First Central Hospital (2019) illustrates the consequence of delayed diagnosis: liver transplantation as the intervention of last resort in a paediatric patient with multi-organ involvement.

The molecular target landscape extends beyond ATP7B itself. Retrieved patent filings and literature identify copper transporter proteins CTR1 (the primary cellular copper importer, encoded by SLC31A1), the copper chaperones ATOX1 and CCS, the parallel transporter ATP7A, and the MURR1 gene — which is associated with copper toxicosis in Bedlington terriers, a veterinary analog model for human copper storage disease — as secondary targets with emerging therapeutic relevance. According to OMIM, Wilson’s disease has been characterised at the molecular level since the ATP7B gene was first isolated, with the foundational nucleic acid sequences described in a 1995 patent by the Trustees of Columbia University.

The Copper Chelation Pipeline: From D-Penicillamine to BC-TTM

The Wilson’s disease chelation pipeline spans six decades of development — from D-penicillamine (DPA), introduced in 1956, to the next-generation bis-choline tetrathiomolybdate (BC-TTM) now representing the deepest commercial IP portfolio in the field. Each generation addresses limitations of its predecessor, with BC-TTM specifically designed to overcome the toxicity profile that has long constrained DPA and trientine use.

D-Penicillamine and Trientine: The Established Standard of Care

D-penicillamine mobilises tissue copper stores and promotes urinary copper excretion; trientine (TETA) functions as a polyamine copper chelator. Both are referenced across multiple patent families as established comparators. Iowa State University Research Foundation and Helmholtz Center Munich patent filings identify their shared liabilities: bone marrow toxicity, nephrotoxicity, hepatotoxicity, anaemia, and autoimmune disease. Philera New Zealand Ltd. has filed patents specifically on triethylenetetramine disuccinate — a more stable salt form of trientine with improved bioavailability — as an improved chelator formulation for both de-coppering and maintenance phases of Wilson’s disease treatment.

BC-TTM (WTX101/ALXN1840): Next-Generation Copper Sequestration

BC-TTM sequesters copper by forming a tripartite complex with albumin and copper in the bloodstream, preventing copper from entering tissues and mobilising it into plasma for clearance. The IP portfolio for BC-TTM is dominated by Alexion Pharmaceuticals (now part of AstraZeneca), spanning at least six jurisdictions — US, WO, CA, JP, CN, and AU — with filing dates ranging from 2019 to 2026. Dosing regimens covered include 15 mg and 30–90 mg once daily, with dedicated filings for adult and paediatric populations (ages 3 to under 18).

“71% of 28 Wilson’s disease patients met the primary endpoint of normalised NCC (57%) or ≥25% NCC reduction (14%) after 24 weeks of BC-TTM treatment, with accompanying neurological improvement — though reversible transaminase elevations occurred in 39% of patients receiving ≥30 mg/day.”

The phase II clinical signal comes from the University Hospital of Heidelberg (2018), which reported that 25% of patients experienced serious adverse events, of which 7 out of 11 were assessed as unlikely to be drug-related. This clinical data, combined with Alexion’s broad patent coverage, positions BC-TTM as the most commercially advanced Wilson’s disease-specific therapeutic in the dataset. Tetrathiomolybdic acid itself — the parent compound — is also covered by Alexion in an Australian patent filed in 2025, extending the IP perimeter of the tetrathiomolybdate class.

Beyond Chelation: Gene Therapy, ASOs, and Novel Biological Modalities

While chelation dominates the current Wilson’s disease treatment landscape, several mechanistically distinct approaches — including AAV-based gene therapy, antisense oligonucleotides, engineered bacterial strains, copper ionophores, and nuclear receptor agonism — represent the next wave of pipeline innovation, each targeting different nodes in the copper metabolism pathway.

AAV-ATP7B Gene Therapy: A Potential Curative Approach

The Foundation for Applied Medical Research (Fundación para la Investigación Médica Aplicada) holds an active Japanese patent on AAV vectors carrying the ATP7B construct. Preclinical data in Wilson’s disease mouse models demonstrated that AAV-ATP7B vector administration significantly reduced urinary copper excretion and liver copper content, restored ceruloplasmin activity, normalised serum transaminase levels and liver histology, and reduced inflammatory infiltration. This is the only gene therapy modality directly retrieved in this dataset, and evidence remains at the preclinical stage — no clinical trial references were captured. Regulatory context from EMA and FDA guidance on paediatric liver gene therapy adds complexity to the clinical translation pathway, though the broader rare liver disease gene therapy infrastructure continues to mature.

Antisense Oligonucleotides Targeting CTR1

ISIS Pharmaceuticals (now Ionis Pharmaceuticals) filed a WO patent in 2014 disclosing ASO compounds targeting CTR1 (copper transporter 1, SLC31A1) — the primary cellular copper importer — to modulate copper-related diseases including Wilson’s disease. The mechanism involves downregulating CTR1-mediated copper uptake, thereby limiting copper accumulation in hepatocytes. No continuation filings or clinical development signals were captured in this dataset, making this an earlier-stage IP position with significant white space for further development.

Engineered Bacteria, Copper Ionophores, and LXR Agonism

Three further modalities represent unconventional but patent-protected approaches. Inventor David Gordon Bermudes holds active US patents on engineered bacterial strains with enhanced copper sequestration capabilities — binding, precipitation, and oxidation/reduction of copper ions — proposed for reducing tissue-available copper in Wilson’s disease, Menkes disease, and potentially neurodegenerative conditions. Texas A&M University has patented elesclomol (a copper ionophore) for restoring cytochrome c oxidase (CcO) activity in subjects with copper metabolism deficiencies caused by mutations in genes including ATP7A, ATP7B, ATOX1, CCS, and CTR1, targeting intracellular copper delivery to mitochondria rather than systemic chelation. Johns Hopkins University filed a WO patent in 2016 disclosing liver X receptor (LXR) agonists as a novel approach based on the correlation between elevated hepatic copper, downregulated lipid metabolism, and liver disease in ATP7b-knockout mouse models — positioning LXR agonism as a means to normalise lipid metabolism disrupted by copper accumulation, independent of chelation.

Biomarker-Guided Dosing and Precision Medicine in Wilson’s Disease

The Wilson’s disease pipeline is moving toward non-ceruloplasmin-bound copper (NCC) ratio-directed treatment initiation and dose modification as a standard framework — a shift from empirical fixed dosing toward a precision medicine paradigm. Alexion patent filings frame an LBC-to-total-copper ratio of 0.21–0.27 or greater as the criterion for initiating BC-TTM therapy, while Orphalan S.A. filed a dedicated WO patent in 2022 specifically on NCC monitoring methodologies to guide copper chelator dosing, including copper speciation assays and dose modification criteria.

Paediatric Wilson’s disease is emerging as a distinct regulatory and clinical target. Multiple Alexion patent families specifically address subjects aged 3 to under 18, with dedicated dosing parameters (15 mg and 30–90 mg once daily), formulation strategies, and safety endpoints. These filings reference multiple provisional applications from 2021 to 2022, indicating active clinical programme development for a population that currently receives only off-label chelation therapy.

Neuroprotection is also emerging as an independent therapeutic endpoint. Alexion’s 2023 JP filing on reducing copper-induced neuronal damage in Wilson’s disease signals a direction to position BC-TTM not only as a copper reduction agent but as a neuroprotective therapy — a framing that could support expanded labelling claims and differentiate the molecule from standard chelators. Preclinical dietary interaction data from Yale University (2019) adds a further dimension: a high-caloric Western diet was shown to accelerate hepatic mitochondrial injury in Wilson’s disease rodent models, providing rationale for dietary co-management as an adjunct strategy alongside pharmacological intervention. This kind of gene-environment interaction data, as tracked by institutions including NIH, is increasingly informing rare disease trial design.

IP Landscape and Strategic Implications for the Wilson’s Disease Pipeline

Alexion Pharmaceuticals (now part of AstraZeneca) holds dominant Wilson’s disease-specific IP in the BC-TTM space, with patent activity spanning at least six jurisdictions and filing dates from 2019 to 2026. Competitors seeking entry into the Wilson’s disease chelation market face significant freedom-to-operate constraints unless targeting formulation innovation, paediatric use, or combination approaches outside Alexion’s current claim scope.

Assignee Landscape

Beyond Alexion, the Iowa State University Research Foundation and Helmholtz Center Munich share a multi-jurisdictional patent family (WO, US, CA, EP, JP, CN) on novel high-affinity copper-binding agents and stabilised chelator formulations, with a pending EP filing in 2025 indicating continued prosecution activity. Philera New Zealand Ltd. (formerly Protemix Corporation) holds active and pending filings on triethylenetetramine disuccinate across US, CA, and JP jurisdictions — representing a near-term competitive threat to D-penicillamine for the maintenance phase of Wilson’s disease treatment, particularly if the improved stability and bioavailability profile is validated clinically. The Foundation for Applied Medical Research holds the primary gene therapy position in this dataset, and ISIS Pharmaceuticals (Ionis Pharmaceuticals) holds the sole ASO-based Wilson’s disease patent retrieved, an earlier filing from 2014 with no continuation signals captured.

White Space and Emerging Opportunities

The multi-target copper metabolism landscape — CTR1, ATOX1, CCS, LXR — represents early-stage IP with significant white space for mechanistically differentiated entrants, particularly in combination regimens targeting both copper overload and secondary metabolic dysfunction. University of Paris Sciences and Letters’ 2022 WO patent on biguanide dimers targeting mitochondrial copper overload, and the University of Chicago’s work on ATOX1/CCS inhibitors with dual utility in Wilson’s disease and cancer, illustrate the breadth of unexploited mechanistic territory. According to patent intelligence tracked via WIPO, rare disease patent filings have accelerated significantly in recent years, driven by orphan drug incentives and precision medicine frameworks — a trend that is amplifying both the pace of Wilson’s disease IP activity and the competitive pressure on established positions.

The gene therapy pipeline maturation trajectory — AAV-ATP7B preclinical data from the Foundation for Applied Medical Research, combined with broader rare liver disease gene therapy infrastructure development — signals a potential curative approach that may enter clinical translation. Current IP is held primarily by academic and foundation entities rather than large biopharma, creating partnering and licensing opportunities for organisations with clinical development capabilities. The paediatric liver gene therapy regulatory environment, however, adds complexity that will require careful navigation.